UNITY
Aug 24 2021
A Phase 2a, Prospective, Multicenter, Randomized, Double-Masked, Sham-Controlled Study to Assess the Safety, Tolerability and Evidence of Activity of a Single Intravitreal Injection of UBX1325 in Patients with Diabetic Macular Edema Sponsor: UNITY Biotechnology, Inc.…
Read MorePEP
Aug 24 2021
Patient Experience and Preference (PEP) Study in nAMD and DME Sponsor: Hoffmann-La Roche Ltd
Read MorePHOTON
Sep 28 2020
A Randomized, Double-Masked, Active-Controlled Phase 2/3 Study of the Efficacy and Safety of High-Dose Aflibercept in Patients with Diabetic Macular Edema (PHOTON) Sponsor: Regeneron Pharmaceuticals CLINICALTRIALS.GOV
Read MoreKINGFISHER
Jun 12 2019
A 12-Month, 2-Arm, Randomized, Double-Masked, Multicenter Phase III Study Assessing the Efficacy and Safety of Brolucizumab vs. Aflibercept in Patients with Visual Impairment Due to Diabetic Macular Edema (KINGFISHER) Sponsor: Novartis Pharmaceuticals clinicaltrials.gov
Read MoreKESTREL
Jun 12 2019
A Two-year, Three-arm, Randomized, Double-masked, Multicenter, Phase III Study Assessing the Efficacy and Safety of Brolucizumab Versus Aflibercept in Adult Patients with Visual Impairment Due to Diabetic Macular Edema (KESTREL) SPONSOR: Novartis Pharmaceuticals CLINICALTRIALS.GOV
Read MoreYOSEMITE/RHONE-X
Jan 28 2019
A Phase III, Multicenter, Randomized, Double-Masked, Active Comparator-Controlled Study to Evaluate the Efficacy and Safety of Faricimab (RO6867461) in Patients with Diabetic Macular Edema (YOSEMITE)
Read More